165 related articles for article (PubMed ID: 36898736)
1. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors.
Caulfield JI; Aizenbud L; Perdigoto AL; Meffre E; Jilaveanu L; Michalek DA; Rich SS; Aizenbud Y; Adeniran A; Herold KC; Austin MR; Kluger H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898736
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
Zhang Z; Sharma R; Hamad L; Riebandt G; Attwood K
Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
5. Response to "
Aizenbud L; Schoenfeld DA; Caulfield JI; Mann JE; Austin MR; Perdigoto AL; Herold KC; Kluger HM
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349129
[No Abstract] [Full Text] [Related]
6. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus induced by immune checkpoint inhibitors.
Zheng Z; Liu Y; Yang J; Tan C; Zhou L; Wang X; Xiao L; Zhang S; Chen Y; Liu X
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3366. PubMed ID: 32543027
[TBL] [Abstract][Full Text] [Related]
8. Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.
Montaudié H; Beranger GE; Reinier F; Nottet N; Martin H; Picard-Gauci A; Troin L; Ballotti R; Passeron T
Pigment Cell Melanoma Res; 2021 Sep; 34(5):978-983. PubMed ID: 33449414
[TBL] [Abstract][Full Text] [Related]
9. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu YC; Liu H; Zhao SL; Chen K; Jin P
Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
[TBL] [Abstract][Full Text] [Related]
10.
Meng XY
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277194
[No Abstract] [Full Text] [Related]
11. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
12. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
13. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
[TBL] [Abstract][Full Text] [Related]
15. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
16. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
17. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
18. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
Shen M; Chen D; Zhao R; Zheng X; Gu Y; Yang T; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1213225. PubMed ID: 37554766
[TBL] [Abstract][Full Text] [Related]
19. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
20. Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors.
Titmuss E; Yu IS; Pleasance ED; Williamson LM; Mungall K; Mungall AJ; Renouf DJ; Moore R; Jones SJM; Marra MA; Laskin JJ; Savage KJ
Curr Oncol; 2024 Mar; 31(4):1865-1875. PubMed ID: 38668043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]